3 active not recruiting, 1 completed, 1 recruiting, 1 unknown. 3 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Recruiting 1, Unknown 1 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Recurrent Endometrial Serous Adenocarcinoma: new trials by email Literature Review of Recurrent Endometrial Serous Adenocarcinoma trials Research Report on Recurrent Endometrial Serous Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab - Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 80 | 2024-03-12 | 2026-08-14 |
| Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma Biospecimen Collection, Computed Tomography, Dostarlimab - Recurrent Endometrial Serous Adenocarcinoma | Phase 2 | Active not recruiting | Casey Cosgrove | 8 | 2023-10-17 | 2026-03-27 |
| Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer Carboplatin, Computed Tomography, Paclitaxel - Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 813 | 2019-08-22 | 2026-10-21 |
| Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration - Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma | Phase 1 | Completed | University of Colorado, Denver | 15 | 2017-10-27 | 2025-10-23 |
| VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer Biopsy, Computed Tomography, Fluorine F 18 Tetrafluoroborate - Metastatic Endometrial Carcinoma, Recurrent Endometrial Adenocarcinoma | Phase 1 | Active not recruiting | Mayo Clinic | 34 | 2017-09-15 | 2026-07-21 |
| Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer 3-Dimensional Conformal Radiation Therapy, Cisplatin, Intensity-Modulated Radiation Therapy - Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Endometrial Mucinous Adenocarcinoma | Phase 2 | Unknown | GOG Foundation | 165 | 2008-02-25 | 2023-03-29 |
Endometrial Neoplasms (2) · Fallopian Tube Neoplasms (2) · Ovarian Neoplasms (2) · Carcinosarcoma (1)
Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Genital Diseases (4) · Genital Diseases, Female (4) · Genital Neoplasms, Female (4) · Neoplasms (4) · Neoplasms by Site (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Adnexal Diseases (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Fallopian Tube Diseases (2) · Gonadal Disorders (2) · Ovarian Diseases (2)
Disulfides (2) · Immunoglobulin G (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · pembrolizumab (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Bevacizumab (1) · Biopsy (1) · Brachytherapy (1) · Carboplatin (1) · Cisplatin (1) · Paclitaxel (1) · Platinum (1) · Radionuclide Generators (1) · Radiosurgery (1)
Casey Cosgrove (1) · GOG Foundation (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · Roswell Park Cancer Institute (1) · University of Colorado, Denver (1)
United States (6) · Canada (2) · Japan (1) · Puerto Rico (1) · South Korea (1)
Casey Cosgrove, MD (1) · Christine Fisher, MD (1) · Emese Zsiros (1) · Jamie N. Bakkum-Gamez, M.D. (1) · Jonathan M Feddock (1) · Ramez N Eskander (1)
PMID 36972022, PMID 37411031, PMID 38431043, PMID 40044930, PMID 40839922
U10CA180868 (2), R01CA207240 (1), U10CA027469 (1)